Captrust Financial Advisors Cardiff Oncology, Inc. Transaction History

Captrust Financial Advisors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$5.18 - $7.24 $2,336 - $3,265	-451 Reduced 52.44%	409 $2,000
Q1 2021 May 17, 2021	BUY	$9.1 - $19.57 $2,730 - $5,871	300 Added 53.57%	860 $8,000
Q4 2020 Feb 16, 2021	SELL	$12.02 - $24.71 $901 - $1,853	-75 Reduced 11.81%	560 $10,000
Q2 2020 Aug 14, 2020	BUY	$0.78 - $5.1 $495 - $3,238	635 New	635 $3,000

12.2M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $174M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.